Charatcharoenwitthaya, Phunchai <br/><br/>
Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.  [electronic resource] 

 -  BMC gastroenterology  Mar 2020 
 - 47 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1471-230X 
<br/><br/><label>Standard No.: </label>10.1186/s12876-020-01196-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adiponectin--blood<br/>Aged<br/>Alanine Transaminase--blood<br/>Benzimidazoles--therapeutic use<br/>Blood Glucose--analysis<br/>Carbamates--therapeutic use<br/>Cholesterol--blood<br/>Drug Combinations<br/>Drug Therapy, Combination<br/>Female<br/>Fluorenes--therapeutic use<br/>Genotype<br/>Hepatitis C, Chronic--drug therapy<br/>Heterocyclic Compounds, 4 or More Rings--therapeutic use<br/>Humans<br/>Imidazoles--therapeutic use<br/>Insulin--blood<br/>Male<br/>Middle Aged<br/>Pyrrolidines<br/>Retrospective Studies<br/>Ribavirin--therapeutic use<br/>Sofosbuvir--therapeutic use<br/>Sustained Virologic Response<br/>Valine--analogs & derivatives<br/>Viral Nonstructural Proteins--antagonists & inhibitors